Mark G. Bandyk M.D., M.P.H., M.S. Associate Professor Department: Department of Urology Business Phone: (904) 244-7340 Business Email: Mark.bandyk@jax.ufl.edu Appointments and Locations About Mark G. Bandyk Dr. Bandyk is a urologic oncologist with a special interest in bladder cancer. He is an expert in robotic and open surgery. Show More Board Certifications Urology Show More Clinical Profile Specialties Urology Show More Publications 2022Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: A systematic review and diagnostic meta-analysis.Urologic oncology.40(2):45-55[DOI] 10.1016/j.urolonc.2021.11.008.[PMID] 34895996.2 citations·PubMed·Publisher's Site2022The Geriatric Nutritional Risk Index Predicts Postoperative Outcomes in Bladder Cancer: A Propensity Score-Matched Analysis.The Journal of urology.207(4):797-804[DOI] 10.1097/JU.0000000000002342.[PMID] 34854753.6 citations·PubMed·Publisher's Site2021An Indirect Comparison of Newer Minimally Invasive Treatments for Benign Prostatic Hyperplasia: A Network Meta-Analysis Model.Journal of endourology.35(4):409-416[DOI] 10.1089/end.2020.0739.[PMID] 32962442.16 citations·PubMed·Publisher's Site2021Intracorporeal versus extracorporeal urinary diversion following robot-assisted radical cystectomy: a meta-analysis, cumulative analysis, and systematic review.Journal of robotic surgery.15(3):321-333[DOI] 10.1007/s11701-020-01174-4.[PMID] 33222043.7 citations·PubMed·Publisher's Site2021MRI and CT bladder segmentation from classical to deep learning based approaches: Current limitations and lessons.Computers in biology and medicine.134():104472-[DOI] 10.1016/j.compbiomed.2021.104472.[PMID] 34023696.10 citations·PubMed·Publisher's Site2021Pathology grade influences competing mortality risks in elderly men with prostate cancer.Urologic oncology.39(8):493.e1-493.e7[DOI] 10.1016/j.urolonc.2020.12.004.[PMID] 33353870.1 citations·PubMed·Publisher's Site2021Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: What about the Negatives?Radiology.298(1):E57-[DOI] 10.1148/radiol.2020202870.[PMID] 33141006.1 citations·PubMed·Publisher's Site2020A Systematic Review and Meta-Analysis of Methods Used to Reduce Infectious Complications Following Transrectal Prostate Biopsy.Urology.144():21-27[DOI] 10.1016/j.urology.2020.06.005.[PMID] 32569659.2 citations·PubMed·Publisher's Site2020Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.Urologic oncology.38(11):826-834[DOI] 10.1016/j.urolonc.2020.03.022.[PMID] 32605736.20 citations·PubMed·Publisher's Site2018Percutaneous ablative cryoimmunotherapy for micrometastaic abscopal effect: No complications.Cryobiology.82():22-26[DOI] 10.1016/j.cryobiol.2018.04.013.[PMID] 29680230.14 citations·PubMed·Publisher's Site2018Rectal Culture and Sensitivity Analysis for Reducing Sepsis Risk After Fiducial Marker Placement.American journal of clinical oncology.41(12):1243-1245[DOI] 10.1097/COC.0000000000000454.[PMID] 29727310.PubMed·Publisher's Site2017Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study.Cancer.123(15):2850-2859[DOI] 10.1002/cncr.30665.[PMID] 28422278.49 citations·PubMed·Publisher's Site1990Characterization of the products of a gene expressed during androgen-programmed cell death and their potential use as a marker of urogenital injury.The Journal of urology.143(2):407-13[DOI] .[PMID] 2299741.76 citations·PubMed·Publisher's Site Show More Office Information Academic Office 3rd Floor, Faculty Clinic653 West 8th Street, FC12Jacksonville, FL 32209(904) 244-7340 Mark.bandyk@jax.ufl.edu Administrative Manager Sammie Adkins(904) 244-7340sammie.adkins@jax.ufl.edu Show More Clinical Research MRI Radiomics Analysis of Muscle Invasive High Grade T1 Bladder Cancer OPEN ENROLLMENT The collection of whole blood and/or other human bio-fluid specimens from subjects clinically diagnosed with cancer and/or other related disease. OPEN ENROLLMENT A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Education Medical Degree1983 · George Washington University, Washington, DC, USATumor Immunology Fellowship1986 · Salk Institute, La Jolla, CA, USASurgery Residency1987 · University of California (San Francisco) School of Medicine, San Francisco, CA, USAUrology Residency1990 · Columbia University, New York, NY, USAUrologic Oncology Fellowship1993 · University of Texas, Houston, TX, USA Show More Multimedia December 1, 2022 Bladder cancer risk factors, warning signs, diagnosis and treatment Show More